HUB's blog

Challenges in preclinical modeling of cancer immunity

Challenges in preclinical modeling of cancer immunity

Published by HUB Organoids on Nov 1, 2022

Learn how to select the right model for your immunotherapy development Over the past decade, immunotherapy has revolutionized oncology. From ipilimumab improving survival by delaying disease progression in advanced melanoma patients to the recent FDA approval of nivolumab for lung cancer. Despite ...

read more